Australia Aims To Drive Etanercept Uptake By Broadening Brenzys Listing

 
• By Aidan Fry

Australian authorities are looking to drive uptake of biosimilar etanercept by broadening a reimbursement listing for MSD’s Brenzys, while an advisory committee continues to ponder listings for trastuzumab biosimilars.

BlueCar
Australia is looking to drive up usage of biosimilar etanercept • Source: Shutterstock

More from Regulation

More from Policy & Regulation